Octapharma Group and Fresenius Kabi have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.
Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from Octapharma's human cell-line platform -- this combination is intended to generate a therapeutic protein with a superior product profile.
Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.
Utilizing process Raman in optimizing cultivated meat production